Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The findings of this work supported that N. oleracea is a rich source of phenolics that can be potential antioxidants and α-glucosidase inhibitors for the management of diabetes.
|
30616569 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-Glucosidase enzymes contribute to the digestion of starch into glucose and are thus attractive therapeutic targets for diabetes.
|
29548257 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enzyme inhibitory potential was assessed against key enzymes linked to global health problems, namely neurodegenerative diseases (acetylcholinesterase), pigmentation (tyrosinase), and diabetes (α-amylase and α-glucosidase).
|
29169111 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-Glucosidase and its inhibitors play a key role in diagnosis and treatment of diabetes.
|
31670357 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-Glucosidase plays an important role in carbohydrate metabolism and is therefore an attractive therapeutic target for the treatment of diabetes, obesity and other related complications.
|
30282319 |
2018 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased α-glucosidase, PEPCK, GLUT-2 and SGLTs levels with the induction of diabetes considerably lowered with TPSE treatment.
|
30399410 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gray, and <i>Salvia officinalis</i> L. decoctions were investigated for their health-benefit properties, in particular with respect to antioxidant activity and inhibitory ability towards key enzymes with impact in diabetes and obesity (α-glucosidase, α-amylase and pancreatic lipase).
|
30513773 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) and α-glucosidase are important targets to treat obesity and diabetes, due to their deep correlation with insulin and leptin signalling, and glucose regulation.
|
28933230 |
2017 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The inhibition of α-glucosidase, a key carbohydrate hydrolyzing enzyme, could serve as one of the effective methodology in both preventing and treating diabetes through controlling the postprandial glucose levels and suppressing postprandial hyperglycemia.
|
29421697 |
2018 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Accordingly, nutritional composition, the content of phytochemical antioxidants, and the inhibitory ability of key enzymes with impacts on obesity and diabetes (α-glucosidase and pancreatic lipase) or on arterial pressure (angiotensin-I converting enzyme), were evaluated.
|
30274353 |
2018 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chalcones, originated from natural product, have been broadly studied their biological activity against various proteins which at the molecular level, are responsible for the progress of the diseases in cancer (e.g. kinases), inflammation (oxidoreductases), atherosclerosis (cathepsins receptor), and diabetes (e.g.α-glucosidase).
|
31808389 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-Glucosidase inhibitors have been approved as therapeutic agents for diabetes.
|
31555798 |
2019 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
On the basis of previous report on promising α-glucosidase inhibitory activity of 5-bromo-2-aryl benzimidazole derivatives, these derivatives were further screened for urease inhibitory and cytotoxicity activity in order to get more potent and non-cytotoxic potential dual inhibitor for the patients suffering from diabetes as well as peptic ulcer.
|
28346872 |
2017 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The animal experiments showed that diabetes increased intestinal disaccharidase activities, accompanied by high mRNA and protein expression of SI complex.
|
21946084 |
2011 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The carbohydrates require metabolism by α-glucosidase before being absorbed into the small intestine, and as a result, this enzyme represents a significant drug target for the effective management of diabetes.
|
30484413 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Scopoletin inhibits α-glucosidase in vitro and alleviates postprandial hyperglycemia in mice with diabetes.
|
30031794 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study sets out to investigate into antioxidant and inhibitory activities of O. argyrea extracts (ethyl acetate, methanol, and water) against key enzymes linked to diabetes (α-amylase, α-glucosidase), Alzheimer's disease (acetylcholinesterase, butyrylcholinesterase), and skin hyperpigmentation (tyrosinase).
|
30081342 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken altogether, in vitro and in vivo experiments suggest that selected natural compounds (curcumin, antroquinonol, HCD, docosanol, tetracosanol, rutin, and actinodaphnine) via molecular docking were confirmed as potential candidates of α-glucosidase and α-amylase inhibitors for treating diabetes.
|
30189596 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lxn significantly inhibited (p < 0.05) the activity of α-amylase and α-glucosidase and could be of medical and nutritional relevance in the treatment of diabetes.
|
28170007 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
As the close correlation between α-glucosidase inhibitors and the treatment of diabetes, in combination with capillary electrophoresis (CE), a method was developed to screen α-glucosidase inhibitors from traditional Chinese medicines (TCMs) by immobilizing α-glucosidase on magnetic nanoparticles.
|
28107971 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-Glucosidase and α-amylase inhibitors from seed oil: A review of liposoluble substance to treat diabetes.
|
26854322 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review provides a comprehensive understanding on the use of flavonoids as αA and αG inhibitors for controlling diabetes.
|
30638035 |
2020 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After adjusting for age, gender, ethnicity, body mass index, smoking status, socioeconomic status, hypertension, hyperlipidaemia, diabetes, duration of diabetes and cardiovascular disease, ACE inhibitors (OR=1.27; 95% CI 1.05 to 1.55), fibrates (OR=1.57; 95% CI 1.05 to 2.35), alpha-glucosidase inhibitors (AGIs) (OR=1.85; 95% CI 1.13 to 3.02) and insulin (OR=1.80; 95% CI 1.11 to 2.93) were significantly associated with the presence of cortical cataract.
|
31272959 |
2020 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The water extracts had the highest antioxidant activity, especially those from roots and flowers, and were further appraised for in vitro inhibition of enzymes implicated on the onset of human ailments, namely acetyl- (AChE) and butyrylcholinesterase (BuChE) for Alzheimer's disease, α-glucosidase and α-amylase for diabetes, and tyrosinase for skin hyperpigmentation disorders.
|
30529825 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-α-glucosidase (AAG) compounds have received great attention due to their potential use in treating diabetes.
|
30769933 |
2019 |